^
Association details:
| Biomarker: | HRAS G12C |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Excerpt:
...we used UMSCC17B cells exhibiting a HRAS Q61L mutation and ORL214, which has a HRAS G12C mutation. Remarkably, we observed that tipifarnib significantly halted tumor growth from as early as 3 days after treatment initiation (n = 6, P < 0.001;…
DOI:
10.1158/1535-7163.MCT-19-0958
